UK Biotech Ervaxx Launches With Focus On ‘Dark Antigens’

Start-Up Raises $17.5m In Series A

 
• By Andrew McConaghie
  
London_Francis_Crick
Ervaxx has been spun out of technology developed at the Francis Crick Institute
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip